Moreover, the publication of EMPA-KIDNEY trial data and sub analyses in 2023–2024 has occasioned calls for prompt testing of SGLT2 inhibitors in pediatric CKD as well (107). This evidence concerns the gene SLC5A2 and chronic kidney disease.